Funding & VC

AstraNu Raises $3.5M Seed for Chip-Scale Medical Imaging Engine

Nokia Bell Labs spinout AstraNu raised $3.5M led by Celesta Capital to commercialize a chip-scale OCT imaging engine more than 10x smaller than conventional systems.

By Daniel Okafor

3 min read

AstraNu Raises $3.5 Million For Chip-Scale Medical Imaging Engine
AstraNu Raises $3.5 Million For Chip-Scale Medical Imaging Enginezathris / pixabay

What's News

  • AstraNu raised $3.5 million in seed funding led by Celesta Capital, with the NJ Innovation Evergreen Fund co-investing
  • The company spun out of Nokia Bell Labs in May 2025 as the first venture from the Celesta-Nokia commercialization collaboration
  • AstraNu's module is more than 10 times smaller than conventional swept-source OCT systems while targeting spectral-domain OCT price levels
  • Funding will expand the photonics team, validate the engine with partners, and prepare for volume manufacturing
  • Ophthalmology is the initial market; ENT, urology and oncology applications are under evaluation by developers

By Daniel Okafor

AstraNu has raised $3.5 million in seed funding to commercialize a chip-scale optical coherence tomography imaging engine for medical-device manufacturers. Celesta Capital led the round. The New Jersey Innovation Evergreen Fund, a program administered by the New Jersey Economic Development Authority, co-invested.

The money has three jobs: expand the photonics development team, validate the imaging engine with commercial partners, and prepare the technology for volume manufacturing. The seed capital moves AstraNu from laboratory development toward manufacturing readiness and customer validation.

Where does the technology come from?

AstraNu spun out of Nokia Bell Labs in May 2025 with backing from Celesta. It was the first venture created through a collaboration between Celesta and Nokia to commercialize technologies developed at Bell Labs.

The company has since demonstrated swept-source optical coherence tomography performance at chip scale. Its next step is placing the technology in partner test environments.

Optical coherence tomography uses light to generate detailed images of tissue. The technology is widely associated with ophthalmology, but it can also support applications in ear, nose, and throat care, urology, oncology, and other fields.

Swept-source OCT can provide faster and deeper imaging than older spectral-domain systems. But the cost and physical size of conventional equipment have limited adoption in some products. That constraint is the opening AstraNu is attacking.

How much smaller is the module?

AstraNu says its module is more than 10 times smaller than conventional swept-source systems. It targets price levels associated with spectral-domain OCT, the older and cheaper class of equipment.

The comparison matters for buyers. A module the size of a chip, priced like legacy hardware, changes what device engineers can build into handheld or compact products.

AstraNu will not build complete medical devices. The company plans to supply the imaging engine to established device, optics, and imaging companies. Those partners integrate the module into their own products and clinical applications.

Ophthalmology is the initial commercial market. It already represents the largest established use of OCT. The company is also working with developers evaluating applications in other medical specialties.

What must the company prove next?

Customer validation will demand more than a working prototype. AstraNu must demonstrate consistent performance, manufacturability, reliability, and suitability for integration into regulated medical products.

Kevin Blalock, President and General Manager of AstraNu, framed the funding as a bridge from lab results to factory output:

This funding enables us to drive our strategy forward by building out our photonics development team and manufacturing readiness ahead of customer volume. Celesta's backing, together with the NJIEF's support, gives us the runway to get our engine into partner testbeds and validate the performance we have achieved.

Matthew Marsh, Managing Partner and CFO of Celesta Capital, said the firm backed AstraNu because it pairs foundational research with a real market shift:

AstraNu is an outstanding example of where we invest: foundational technology from one of the world's leading research labs, with the potential to change what is possible in a large and established market. By delivering a new cost and performance package, AstraNu is opening this imaging technology to entirely new applications and markets. Scaling a technology like this from the lab into volume production requires disciplined operations and commercial partners – supporting founders in this work is what we do. Celesta is delighted to lead this round alongside NJEDA, and to continue our partnership with Nokia to build globally competitive companies around market-shifting technologies.

The bet now rests on execution. If AstraNu can hold chip-scale performance through volume manufacturing, the $3.5 million seed could unlock OCT markets that conventional swept-source hardware never reached.

Source: pulse2.com

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.

2,360 articles

Related articles

« Previous articleNext article »